28 Mar 22
tranScrip, the fast-growing contract drug development organisation which supports the development and lifecycle of medicines, has acquired Dublin-based Real Regulatory, a highly respected business specialising in European regulatory affairs, quality systems and compliance for medical products.
The strategic acquisition significantly expands tranScrip’s regulatory affairs capabilities, strengthening its ability to provide comprehensive support to its customers. The deal is the first acquisition made by tranScrip since it secured the backing of private equity investor Palatine in 2021 via its dedicated Impact Fund.
Headquartered in Dublin, with branch offices in Ely, Cambridgeshire and Malta, Real Regulatory was founded 20 years ago. It specialises in European regulatory affairs, quality systems and compliance for products including medicines, medical devices and drug device combinations.
Across its three locations Real Regulatory has a highly experienced team supporting a global client-base. Its founder and Managing Director, Karen Real, who has more than 35 years’ experience in the pharmaceutical industry, will remain with the business moving forward.
Dr Marcin Mankowski, Managing Partner at tranScrip said: “We are excited to have completed this highly strategic and important acquisition, the first since the Palatine Impact investment last year.
“We see major synergies between tranScrip and Real Regulatory teams. Regulatory affairs is a fundamental element of drug development from pre-clinical stages to product registration and expanding our offering in this key area is critical for our continuous growth.
“The cultural alignment between the two businesses is really strong with a shared commitment to technical excellence and a relentless focus on delivering an outstanding strategic and operational service to our clients.”
Marcin added: “We are looking forward to working with Karen and her team and introducing them to our clients. This acquisition will support our strong, continued growth which has seen us increase our capabilities in clinical pharmacology, medical affairs, oncology and clinical operations and expand our team by 30% since the Palatine investment last year.”
Karen Real commented: “I am delighted to be joining tranScrip and having got to know their people over the last few months, I know there is a brilliant business and cultural fit between the two companies, which I am sure will be highly beneficial to the Real Regulatory team and of course to both organisations’ clients.
“As Real Regulatory enters its third decade in business I feel incredibly energised by the opportunities this combination with tranScrip will deliver, and I can’t wait to get working on helping to drive the growth.”
Tristan Craddock, Impact Partner at Palatine added: “We are delighted to support this transformational acquisition which adds a skilled and experienced regulatory capability to tranScrip’s differentiated offering, and also an international presence with offices in Dublin and Malta, which can be a further platform for growth moving forward.
“Since our investment 14 months ago we have seen significant organic growth and we look forward to this momentum continuing following this important and value-enhancing deal.”
Real Regulatory press release: Real Regulatory is now a subsidiary of tranScrip
Press release issued by Influential on behalf of tranScrip and Palatine Private Equity.
For further information please contact: Chris Barry on 07733 103693
tranScrip is a leading contract drug development organisation which supports the development and lifecycle of medicines.
We bring innovative solutions to pharma and biotech companies global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements.
Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches.
In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.
Palatine is a UK mid-market private equity investor focused on delivering returns through sustainable growth by building on solid foundations with a commitment to the environment and society.
We see private equity as a force for good. A positivity born of generating returns in the right way.
Founded in 2005 by partners Gary Tipper, Ed Fazakerley and Tony Dickin, we have successfully raised four Buyout Funds and we are the first private equity firm in our market to raise a returns-focused Impact Fund.
Our approach is built on three solid foundations: investing in relationships, identifying the appropriate value enhancement strategies and improving sustainability outcomes through our pioneering ESG framework.
We seek to partner with management teams across the business services, financial services, health, education and technology sectors.
We invest from two funds:
Buyout Fund: Sustainable returns
Investing between £10m – £30m in dynamic and visionary management teams looking to drive their business through their next phase of sustainable growth.
Impact Fund: Returns with purpose
Investing £5m – £20m in commercially driven businesses with a mission to positively impact on society or the environment.
We are headquartered in Manchester with offices in London and Birmingham.
We have teams of life science and R&D experts to help achieve your goals and seize opportunities. Whatever your project requires, we have the people to meet your needs.
